Vesilute

Vesilute — Bladder / Urinary Bioregulator

Vesilute is a Khavinson-class short-chain bioregulator peptide that restores youthful gene expression in bladder / urinary tissue.

Peptide Specifications

Parameter	Value
Sequence	Lys-Glu-Trp
Mass	447.5 g/mol
Purity	>98.0%
Target Organ	Bladder / Urinary

Figure 1: Vesilute Organ-Specific Bioregulation

Tissue-Specific Mechanism

1. Tripeptide targeting urothelial lining of the bladder.
2. Restores GAG layer integrity (protective mucous barrier).
3. Normalizes detrusor muscle contractility.
4. Decreases mast cell infiltration in interstitial cystitis.
5. Promotes urothelial cell regeneration.

Figure 2: Bladder / Urinary Regeneration Curve

Research Results

• 1: Khavinson peptide for bladder tissue homeostasis.
• 2: Improves quality-of-life in overactive bladder models.
• 3: Repairs bladder wall at the cellular level.

Urinary Tract & Bladder Bioregulator

Vesilute (Lys-Glu-Asp) is a synthetic tripeptide bioregulator derived from urinary bladder and urinary tract tissue, targeting the transitional epithelium (urothelium), detrusor smooth muscle, and pelvic floor signaling pathways that govern lower urinary tract function. Age-related urinary dysfunction—including overactive bladder, decreased bladder capacity, nocturia, and urinary urgency—affects 30–40% of adults over 65. Vesilute addresses these through epigenetic restoration of urothelial barrier function, detrusor contractility regulation, and neural control gene expression.

1. Vesilute modulates urothelial gene expression, normalizing uroplakin protein production (UPK1a, UPK2, UPK3a) that forms the impermeable apical plaque barrier.
2. Tight junction protein expression between urothelial cells (claudin-4, occludin) is restored, preventing urine solute leakage that triggers sensory nerve irritation.
3. Detrusor smooth muscle contractile gene expression (smooth muscle myosin, caldesmon) is normalized, restoring appropriate contraction force and timing.
4. Muscarinic receptor (M2, M3) expression on detrusor is modulated, rebalancing the parasympathetic control of bladder contraction.
5. Suburothelial sensory nerve gene expression is normalized, reducing the afferent hyperactivity that drives urgency and frequency symptoms.

Lower Urinary Tract Research

• Overactive Bladder: Vesilute’s restoration of urothelial barrier function and sensory nerve normalization directly targets the pathophysiology of overactive bladder syndrome.
• Nocturia: Improved bladder capacity and reduced sensory urgency contribute to decreased nocturnal voiding frequency.
• Gender-Neutral: Lower urinary tract dysfunction affects both sexes. Vesilute targets shared urothelial/detrusor pathways relevant to both male and female urinary aging.
• Combination: In males, combined with Prostamax (prostate bioregulator) for comprehensive lower urinary tract support. In females, combined with hormonal support protocols.
• Protocol: 1–2 capsules daily for 20–30 days. Courses repeated every 3–6 months based on symptom assessment and urodynamic parameters.